Skip to main content
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. — Investor Relations & Filings

Ticker · PRQR ISIN · NL0010872495 LEI · 549300NGS2FJGGDBGS06 US Professional, scientific and technical activities
Open in API
Filings indexed 353 across all filing types
Latest filing 2026-06-02 Declaration of Voting R…
Country NL Netherlands
Listing US PRQR

About ProQR Therapeutics N.V.

https://www.proqr.com/

ProQR Therapeutics N.V. is a company focused on the discovery and development of transformative RNA therapies for severe genetic disorders. The company's core is its proprietary Axiomer® RNA editing platform, a novel technology designed to make precise edits to RNA. This platform leverages the body's own natural editing machinery, specifically ADAR (Adenosine Deaminase Acting on RNA) enzymes, to correct genetic mutations at the RNA level. By targeting the root cause of diseases, Axiomer® has the potential to create a new class of medicines for a range of rare and common conditions with high unmet medical needs. ProQR advances its technology through internal development programs and strategic collaborations to bring potential new treatments to patients.

Recent filings

Filing Released Lang Actions
FORM 6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a Form 6-K submission by a foreign private issuer reporting the Annual General Meeting results, including vote counts for each agenda item and board committee composition. This clearly constitutes an official declaration of shareholder voting results from the AGM. Hence, it falls under Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-06-02 English
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
Regulatory Filings Classification · 73% confidence The document is a Form 6-K filing by a foreign private issuer, running under 2,789 characters and merely stating that unaudited Q1 financial statements (Exhibit 99.1) and a press release (Exhibit 99.2) are furnished. It does not contain the full interim report itself but announces attached exhibits. Under the Menu vs Meal rule, short SEC cover filings that simply furnish or reference reports belong in Regulatory Filings (RNS).
2026-05-12 English
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
Regulatory Filings Classification · 85% confidence The document is a Form 6-K filing by a foreign private issuer under the Securities Exchange Act, furnishing an Exhibit (a press release announcing quarterly results). It does not contain the full financial report itself but is a regulatory submission of a press release. This falls under the general “Regulatory Filings” category as a miscellaneous SEC filing rather than an actual earnings release document.
2026-05-12 English
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
Proxy Solicitation & Information Statement Classification · 80% confidence The filing is a Form 6-K by ProQR, a foreign private issuer, furnishing materials related to its 2026 Annual General Meeting: a notice of meeting, explanatory notes to the agenda, proposed amendments, and a proxy form. These exhibits are classic proxy solicitation and information statement materials sent to shareholders to request votes. Therefore, it best fits the Proxy Solicitation & Information Statement category (PSI), not merely a generic regulatory announcement.
2026-05-04 English
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, ProQR Therapeutics N.V., with the SEC. It announces the nomination of a new board member, Dr. Lykke Hinsch Gylvin, to the Board of Directors. The document includes a press release as Exhibit 99.1 and references incorporation by reference into registration statements. The content is an announcement of a board/management change rather than a full report or financial statement. The document length is short (2105 characters), and it primarily serves as a notification of management change. Therefore, the appropriate classification is Board/Management Information (MANG).
2026-04-30 English
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, ProQR Therapeutics N.V., with the SEC. It references a press release dated April 8, 2026, about a partnership and formation of an AI advisory board, attached as Exhibit 99.1. The document is short (2108 characters) and primarily serves to report this press release. There is no substantive financial data, detailed financial statements, or comprehensive report content. The document is an announcement of information rather than the information itself. According to the rules, such filings are best classified as Regulatory Filings (RNS) because they do not fit into other specific categories and are not full reports or presentations.
2026-04-08 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.